Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung

Summary

The purpose of this study is to determine the 4-month Progression-Free Survival (PFS), with demonstrated increase in tumor doubling time, of eligible subjects treated with pazopanib according to RECIST version 1.1 guidelines.

Timeline

Start

2013-04

Primary completion

2017-01

Completion

2017-05

Outcome

Outcome not reported

Stopped (Enrollment): “low accrual”

Publications

• Frankel P, Ruel C, Uche A, Choy E, Okuno S, Somiah N, Chow WA. Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement. J Oncol. 2022 Jan 15;2022:3691025. doi: 10.1155/2022/3691025. eCollection 2022.

Drugs

Indications